Cerus CORP 8-K filings

Cerus Corporation reported a 10% year-over-year increase in product revenue to $57.4 million for the second quarter of 2026, and raised the lower end of its full-year product revenue guidance.

Cerus Corporation announces William Greenman's transition from CEO to Executive Chairman, with updated compensation and service terms.

Cerus Corporation has entered into new credit agreements, amending and restating its existing term and revolving loan facilities, providing up to $65 million in term loans and $30 million in revolving credit.

Cerus Corporation's stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing share availability, and ratified the appointment of Ernst & Young LLP.

Cerus Corporation has implemented a new severance plan for key executives to provide standardized benefits in the event of termination following a change in control.

Cerus Corporation announces a leadership transition with Vivek Jayaraman promoted to President and CEO, effective July 1, 2026, while William Obi Greenman transitions to Executive Chairman.

Cerus Corporation announced robust full-year and fourth-quarter 2025 financial results, highlighted by record product revenue and positive non-GAAP adjusted EBITDA for the second consecutive year, alongside 2026 product revenue guidance.

Timothy L. Moore, a director at Cerus Corporation, will not stand for re-election at the 2026 annual meeting of stockholders.

Cerus Corporation announced preliminary Q4 and full-year 2025 product revenue, showing significant growth, and provided positive 2026 revenue guidance and key development milestones.

Cerus Corporation announced record third-quarter 2025 financial results, with total revenue up 19% and product revenue up 15% year-over-year, leading to raised full-year 2025 product revenue guidance.

Cerus Corporation reported strong second-quarter 2025 financial results, with total revenue increasing 19% year-over-year and product revenue up 16%, leading to a raised full-year product revenue guidance.

Cerus Corporation announced the immediate retirement of Board Chair Daniel N. Swisher, Jr., and the subsequent appointment of CEO William M. Greenman as the new Chair and Frank Witney, Ph.D., as Lead Independent Director.

Cerus Corporation announced that its stockholders approved the amendment and restatement of the 2024 Equity Incentive Plan and elected two directors at its 2025 Annual Meeting.

Cerus Corporation announces a 13% increase in first-quarter product revenue and reiterates its full-year revenue guidance of $194-$200 million.

Cerus Corporation reports a 15% increase in full-year 2024 product revenues and reiterates its 2025 product revenue guidance.

Gail Schulze, a Cerus Corporation director, will not seek re-election at the 2025 annual meeting.

Cerus Corporation reported preliminary full-year 2024 product revenue of $180.3 million, exceeding prior guidance, and anticipates 2025 revenue between $194-$200 million.

Cerus Corporation has extended its supply agreement with Porex Corporation for platelet wafers and plasma disks through December 31, 2027, with fixed pricing for the first two years.

Cerus Corporation announced a 16% increase in third-quarter product revenue and raised its full-year 2024 product revenue guidance to $177-$179 million.

Cerus Corporation announced a new $248 million contract with BARDA to advance its red blood cell program in the U.S., while its CE Mark review in Europe concluded without approval.

Cerus Corporation announced a 20% increase in first-half product revenue and raised its full-year 2024 product revenue guidance range to $175-178 million.

Cerus Corporation has appointed Dean Gregory, a seasoned executive in the blood transfusion and cell therapy industry, to its Board of Directors, effective July 1, 2024.

Cerus Corporation's stockholders approved the 2024 Equity Incentive Plan, elected three directors, and ratified the selection of Ernst & Young LLP as the independent auditor at their annual meeting on June 5, 2024.

Cerus Corporation announced a 24% year-over-year increase in product revenue for the first quarter of 2024, driven by strong sales of its INTERCEPT Blood System for Platelets.

Cerus Corporation's Phase 3 clinical trial for its INTERCEPT Blood System for Red Blood Cells met its primary efficacy endpoint, demonstrating non-inferiority compared to conventional red blood cells in cardiovascular surgery patients.

Cerus Corporation announced its fourth quarter and full-year 2023 financial results, highlighting adjusted EBITDA breakeven for the quarter and a narrowed net loss.